97 related articles for article (PubMed ID: 30306310)
21. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.
Insinga RP; Dasbach EJ; Elbasha EH; Liaw KL; Barr E
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):709-15. PubMed ID: 17416761
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
23. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
24. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients.
Gomez-Lobo V; Whyte T; Kaufman S; Torres C; Moudgil A
Pediatr Transplant; 2014 May; 18(3):310-5. PubMed ID: 24484551
[TBL] [Abstract][Full Text] [Related]
27. Awareness and knowledge about human papillomavirus infection and vaccination among women in UAE.
Ortashi O; Raheel H; Shalal M; Osman N
Asian Pac J Cancer Prev; 2013; 14(10):6077-80. PubMed ID: 24289628
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
29. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
30. The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents.
Schlenker B; Schneede P
Eur Urol Focus; 2019 Jan; 5(1):42-45. PubMed ID: 30262198
[TBL] [Abstract][Full Text] [Related]
31. Awareness and attitude relating to the human papilloma virus and its vaccines among pediatrics, obstetrics and gynecology specialists in Turkey.
Tolunay O; Celik U; Karaman SS; Celik T; Resitoglu S; Donmezer C; Aydin F; Baspinar H; Mert MK; Samsa H; Arli S
Asian Pac J Cancer Prev; 2014; 15(24):10723-8. PubMed ID: 25605165
[TBL] [Abstract][Full Text] [Related]
32. HPV prophylactic vaccination in males improves the clearance of semen infection.
Foresta C; Garolla A; Parisi S; Ghezzi M; Bertoldo A; Di Nisio A; De Toni L
EBioMedicine; 2015 Oct; 2(10):1487-93. PubMed ID: 26629543
[TBL] [Abstract][Full Text] [Related]
33. Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease.
Ghelardi A; Marrai R; Bogani G; Sopracordevole F; Bay P; Tonetti A; Lombardi S; Bertacca G; Joura EA
Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33503866
[TBL] [Abstract][Full Text] [Related]
34. Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries.
Gallagher KE; Kelly H; Cocks N; Dixon S; Mounier-Jack S; Howard N; Watson-Jones D
Papillomavirus Res; 2018 Dec; 6():33-40. PubMed ID: 30352297
[TBL] [Abstract][Full Text] [Related]
35. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
Steben M; Tan Thompson M; Rodier C; Mallette N; Racovitan V; DeAngelis F; Stutz M; Rampakakis E
J Obstet Gynaecol Can; 2018 Dec; 40(12):1635-1645. PubMed ID: 30341021
[TBL] [Abstract][Full Text] [Related]
36. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
37. Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men.
Giuliani M; Latini A; Colafigli M; Benevolo M; Rollo F; Zaccarelli M; Giuliani E; Moretto D; Giglio A; Rezza G; Cristaudo A; Donà MG
Future Microbiol; 2018 Oct; 13():1463-1472. PubMed ID: 30311788
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution's Experience.
Petrillo M; Dessole M; Tinacci E; Saderi L; Muresu N; Capobianco G; Cossu A; Dessole S; Sotgiu G; Piana A
Vaccines (Basel); 2020 Jan; 8(1):. PubMed ID: 31991753
[TBL] [Abstract][Full Text] [Related]
39. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
Sand FL; Kjaer SK; Frederiksen K; Dehlendorff C
Int J Cancer; 2020 Aug; 147(3):641-647. PubMed ID: 31648368
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis.
Jentschke M; Kampers J; Becker J; Sibbertsen P; Hillemanns P
Vaccine; 2020 Sep; 38(41):6402-6409. PubMed ID: 32762871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
